Now showing items 1-3 of 3

    • CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites. 

      Sood, D; Johnson, N; Jain, P; Siskos, AP; Bennett, M; Gilham, C; Busana, MC; Peto, J; Dos-Santos-Silva, I; Keun, HC; Fletcher, O (2017-01)
      BACKGROUND: Endogenous sex hormones are well-established risk factors for breast cancer; the contribution of specific oestrogen metabolites (EMs) and/or ratios of specific EMs is less clear. We have previously identified ...
    • Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. 

      Johnson, N; Dudbridge, F; Orr, N; Gibson, L; Jones, ME; Schoemaker, MJ; Folkerd, EJ; Haynes, BP; Hopper, JL; Southey, MC; Dite, GS; Apicella, C; Schmidt, MK; Broeks, A; Van't Veer, LJ; Atsma, F; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Ekici, AB; Renner, SP; Sawyer, E; Tomlinson, I; Kerin, M; Miller, N; Burwinkel, B; Marme, F; Schneeweiss, A; Sohn, C; Guénel, P; Truong, T; Cordina, E; Menegaux, F; Bojesen, SE; Nordestgaard, BG; Flyger, H; Milne, R; Zamora, MP; Arias Perez, JI; Benitez, J; Bernstein, L; Anton-Culver, H; Ziogas, A; Clarke Dur, C; Brenner, H; Müller, H; Arndt, V; Dieffenbach, AK; Meindl, A; Heil, J; Bartram, CR; Schmutzler, RK; Brauch, H; Justenhoven, C; Ko, YD; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Matsuo, K; Dörk, T; Bogdanova, NV; Antonenkova, NN; Lindblom, A; Mannermaa, A; Kataja, V; Kosma, VM; Hartikainen, JM; Chenevix-Trench, G; Beesley, J; Wu, AH; Van den Berg, D; Tseng, CC; Lambrechts, D; Smeets, D; Neven, P; Wildiers, H; Chang-Claude, J; Rudolph, A; Nickels, S; Flesch-Janys, D; Radice, P; Peterlongo, P; Bonanni, B; Pensotti, V; Couch, FJ; Olson, JE; Wang, X; Fredericksen, Z; Pankratz, VS; Giles, GG; Severi, G; Baglietto, L; Haiman, C; Simard, J; Goldberg, MS; Labrèche, F; Dumont, M; Soucy, P; Teo, S; Yip, CH; Phuah, SY; Cornes, BK; Kristensen, VN; Grenaker Alnæs, G; Børresen-Dale, AL; Zheng, W; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Andrulis, IL; Knight, JA; Glendon, G; Mulligan, AM; Devillee, P; Figueroa, J; Chanock, SJ; Lissowska, J; Sherman, ME; Hall, P; Schoof, N; Hooning, M; Hollestelle, A; Oldenburg, RA; Tilanus-Linthorst, M; Liu, J; Cox, A; Brock, IW; Reed, MW; Cross, SS; Blot, W; Signorello, LB; Pharoah, PD; Dunning, AM; Shah, M; Kang, D; Noh, DY; Park, SK; Choi, JY; Hartman, M; Miao, H; Lim, WY; Tang, A; Hamann, U; Försti, A; Rüdiger, T; Ulmer, HU; Jakubowska, A; Lubinski, J; Jaworska-Bieniek, K; Durda, K; Sangrajrang, S; Gaborieau, V; Brennan, P; McKay, J; Slager, S; Toland, AE; Vachon, C; Yannoukakos, D; Shen, CY; Yu, JC; Huang, CS; Hou, MF; González-Neira, A; Tessier, DC; Vincent, D; Bacot, F; Luccarini, C; Dennis, J; Michailidou, K; Bolla, MK; Wang, J; Easton, DF; García-Closas, M; Dowsett, M; Ashworth, A; Swerdlow, AJ; Peto, J; dos Santos Silva, I; Fletcher, O (2014-01)
      We have previously shown that a tag single nucleotide polymorphism (rs10235235), which maps to the CYP3A locus (7q22.1), was associated with a reduction in premenopausal urinary estrone glucuronide levels and a modest ...
    • Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. 

      Cortes, J; Tamura, K; DeAngelo, DJ; de Bono, J; Lorente, D; Minden, M; Uy, GL; Kantarjian, H; Chen, LS; Gandhi, V; Godin, R; Keating, K; McEachern, K; Vishwanathan, K; Pease, JE; Dean, E (2018-05)
      BACKGROUND: Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated ...